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Potent Paracrine Effects of human 
induced Pluripotent Stem Cell-
derived Mesenchymal Stem Cells 
Attenuate Doxorubicin-induced 
Cardiomyopathy
Yuelin Zhang1, Xiaoting Liang1, Songyan Liao1, Weixin Wang2, Junwen Wang2, Xiang Li1, 
Yue Ding3, Yingmin Liang1, Fei Gao3, Mo Yang3, Qingling Fu4, Aimin Xu1,5, Yuet-Hung Chai1, 
Jia He3, Hung-Fat Tse1,5 & Qizhou Lian1,3,5
Transplantation of bone marrow mesenchymal stem cells (BM-MSCs) can protect cardiomyocytes 
against anthracycline-induced cardiomyopathy (AIC) through paracrine effects. Nonetheless the 
paracrine effects of human induced pluripotent stem cell-derived MSCs (iPSC-MSCs) on AIC are poorly 
understood. In vitro studies reveal that doxorubicin (Dox)-induced reactive oxidative stress (ROS) 
generation and cell apoptosis in neonatal rat cardiomyocytes (NRCMs) are significantly reduced 
when treated with conditioned medium harvested from BM-MSCs (BM-MSCs-CdM) or iPSC-MSCs 
(iPSC-MSCs-CdM). Compared with BM-MSCs-CdM, NRCMs treated with iPSC-MSCs-CdM exhibit 
significantly less ROS and cell apoptosis in a dose-dependent manner. Transplantation of BM-MSCs-
CdM or iPSC-MSCs-CdM into mice with AIC remarkably attenuated left ventricular (LV) dysfunction 
and dilatation. Compared with BM-MSCs-CdM, iPSC-MSCs-CdM treatment showed better alleviation 
of heart failure, less cardiomyocyte apoptosis and fibrosis. Analysis of common and distinct cytokines 
revealed that macrophage migration inhibitory factor (MIF) and growth differentiation factor-15 
(GDF-15) were uniquely overpresented in iPSC-MSC-CdM. Immunodepletion of MIF and GDF-15 in 
iPSC-MSCs-CdM dramatically decreased cardioprotection. Injection of GDF-15/MIF cytokines could 
partially reverse Dox-induced heart dysfunction. We suggest that the potent paracrine effects of 
iPSC-MSCs provide novel “cell-free” therapeutic cardioprotection against AIC, and that MIF and GDF-
15 in iPSC-MSCs-CdM are critical for these enhanced cardioprotective effects.
Anthracyclines, including doxorubicin (Dox), are common chemotherapeutic agents used for the treat-
ment of a wide variety of malignancies1. Nonetheless they are well known to cause dose-dependent, 
progressive myocardial damage that can manifest to variable degrees, from subclinical myocardial dys-
function to severe heart failure and even death2. The prevalence of anthracycline-induced cardiomyopa-
thy (AIC) is increasing as more cancer patients survive, and is a potential cause of significant morbidity 
and mortality3. Although pharmacological therapies, including the use of angiotensin converting enzyme 
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inhibitors4,5 alone or with beta-blockers, may limit AIC, the only curative therapy for severe AIC is heart 
transplantation6. Recently, stem cell based therapy has been investigated7–9 as treatment for cardiovascu-
lar diseases, including AIC.
Among the different types of stem cell under investigation, bone marrow (BM) derived mesenchy-
mal stem cells (MSCs)(BM-MSCs) show promising results in the treatment of heart failure with several 
advantages, including easy isolation and expansion and low immunogenicity10,11. The majority of the 
therapeutic effects of MSCs have been attributed to their paracrine effects12–16. MSCs can secrete a wide 
array of cytokines and growth factors for cardiac repair via modulation of the inflammatory response, 
inhibition of cell necrosis and apoptosis, and promotion of angiogenesis17,18. Although MSCs derived 
from different tissues share many common properties, they also display distinct paracrine potential. 
MSCs can be derived from either adult somatic tissue or pluripotent stem cells. Currently, BM-MSCs are 
the most common cell source investigated in clinical trials, although their limited proliferative capacity 
and large variability have hindered their application19,20. We have successfully derived functional MSCs 
from human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs): both exhibit supe-
rior therapeutic efficacy and paracrine actions for cardiovascular repair to BM-MSCs21–23. Unfortunately 
the potential risk of tumor formation and poor cell engraftment remain a major hurdle to the ther-
apeutic application of MSCs derived from pluripotent stem cells. Nevertheless the administration of 
MSC-derived conditioned medium (CdM) that contains different cytokines can address these issues 
although the potential therapeutic benefits are unclear. In this study, we sought to investigate whether 
CdM derived from iPSCs-MSCs can confer a therapeutic effect in AIC.
Here, we demonstrate that human iPSC-MSCs-CdM effectively attenuates Dox-induced cardiomyo-
pathy in mice by prevention of cardiomyocyte apoptosis and reduction of reactive oxidative stress (ROS) 
generation. In addition, our results reveal that iPSC-MSCs-CdM enriched with growth differentiation 
factor-15 (GDF-15) and macrophage migration inhibitory factor (MIF) provides better cardioprotection 
against AIC than BM-MSCs-CdM.
Results
iPSC-MSCs-CdM effectively reduces Dox-induced oxidative stress and apoptosis in-vitro. We 
sought to determine whether soluble factors of MSCs play a key protective role against Dox-induced 
cardiomyopathy. Neonatal rat cardiomyocytes (NRCMs) were cultured in-vitro with or without MSCs 
using a transwell to avoid direct cell-cell communication under challenge of Dox for 24 hours (Fig. 1a-i). 
3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay demonstrated that co-culture 
with BM-MSCs or iPSC-MSCs significantly increased cell viability of NRCMs compared with the absence 
of MSCs (Dox group, Fig.  1a-ii). In addition, iPSC-MSCs exhibited better protective potential against 
Dox-induced NRCM death than BM-MSCs (Fig. 1a-ii, P < 0.01).
Excessive ROS generation and cardiomyocyte apoptosis have been proposed as the major mecha-
nisms of AIC. We further investigated whether the cardioprotective effects of MSCs-CdM are mediated 
through attenuation of Dox-induced oxidative stress and apoptosis in NRCMs. In living cell culture of 
NRCMs, 2′ , 7′ -Dichlorodihydrofluorescein dilacerate (H2DCFDA) and terminal deoxynucleotidal trans-
ferase mediated dUTP nick end-labeling (TUNEL) staining was used to measure ROS generation and 
apoptosis, respectively, in the presence or absence of MSCs-CdM under challenge of Dox for 24 hours 
(Fig. 1b,c). H2DCFDA staining revealed that the ROS score was significantly increased approximately five 
fold in the Dox group compared with the control group (Fig.  1b-i,ii). Administration of CdM derived 
from BM-MSCs or iPSC-MSCs significantly decreased the fluorescence intensity of H2DCFDA stain-
ing compared with the Dox group (Fig. 1b-ii; P < 0.01). Similarly, the concentration of malonyldialde-
hyde (MDA) in the Dox group was dramatically increased compared with the control group (Fig. 1b-iii, 
3.76 ± 0.015 μ mol/g protein vs. 0.83 ± 0.014 μ mol/g protein; P < 0.01). Administration of CdM derived 
from BM-MSCs or iPSC-MSCs significantly decreased MDA compared with the Dox group (Fig. 1b-iii; 
P < 0.01).
TUNEL staining revealed that apoptosis of NRCMs in the Dox group was significantly increased 
compared with the control group (Fig.  1c-i,ii, 31.75 ± 3% vs. 1.75 ± 0.9%; P < 0.01). Administration of 
CdM derived from BM-MSCs or iPSC-MSCs significantly decreased apoptosis of NRCMs compared 
with the Dox group (Fig. 1c-ii; P < 0.01). Notably, both the fluorescence intensity of H2DCFDA staining 
(Fig. 1b-ii; P < 0.01) and the apoptotic rate of NRCMs (Fig. 1c-ii, 7.25 ± 1.25% vs. 20.75 ± 1.7%; P < 0.01) 
were significantly lower following administration of iPSC-MSCs-CdM than following BM-MSCs-CdM. 
The concentration of MDA in the iPSC-MSCs-CdM group was also significantly lower than in the 
BM-MSC-CdM group (Fig.  1b-iii, 1.45 ± 0.04 μ mol/g protein vs. 2.69 ± 0.07 μ mol/g protein; P < 0.01). 
The cardioprotection afforded by iPSC-MSCs-CdM was dose-dependent (Fig.  1d). Concentration of 
MDA generation was decreased with increased concentration of iPSC-MSCs-CdM treatment in NRMCs 
(Fig.  1d-i; P < 0.01). Compared with the iPSC-MSCs-CdM-10 μ l and iPSC-MSCs-CdM-20 μ l group, 
concentration of MDA was most remarkably reduced in the iPSC-MSCs-CdM-50 μ l group (Fig.  1d-i; 
P < 0.01). Similarly, the Dox-induced apoptotic rate of NRCMs was dramatically attenuated in the 
iPSC-MSCs-CdM-50 μ l group, compared with the iPSC-MSCs-CdM-10 μ l and iPSC-MSCs-CdM-20 μ l 
group (Fig. 1d-ii; P < 0.01).
These findings suggest that soluble factors secreted by MSCs in the CdM are likely to confer impor-
tant protective effects against Dox-induced oxidative stress and apoptosis in NRCMs via a paracrine 
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Figure 1. Paracrine effects of MSCs on Dox-induced oxidative stress and apoptosis of neonatal rat 
cardiomyocytes (NRCMs) in-vitro. a) 1 × 104 iPSC-MSCs or BM-MSCs were seeded on 0.3 μ m pore size 
transwell inserts and 1 × 104 NRCMs were seeded on the bottom of a 96-well culture plate with or without 
presence of 1 μ M Dox. 24 hours later, the transwell inserts were removed and MTT assay was used to measure 
NRCMs cell viability (i). The percentage of cell viability of each group was calculated from triple experiments 
(ii) (*p < 0.01 vs. control group; #p < 0.01 vs. Dox group; †p < 0.01 vs. BM-MSCs-CdM group). b,c) NRCMs 
were treated with or without MSCs-CdM (BM-MSCs-CdM or iPSC-MSCs-CdM) under challenge of 1 μ M Dox 
for 24 hours. In living cell culture conditions, H2DCFDA (b-i) and TUNEL (c-i) staining were used to measure 
ROS generation and cell apoptosis respectively. Quantitative measurement of ROS (b-ii) and apoptotic rate 
(c-ii) was counted from five viewing fields in each group and triple experiments were performed (*p < 0.01 vs. 
control group; #p < 0.01 vs. Dox group; †p < 0.01 vs. BM-MSCs-CdM group). The concentration of MDA (b-iii) 
among the different groups was also measured (*p < 0.01 vs. control group; #p < 0.01 vs. Dox group; †p < 0.01 
vs. BM-MSCs-CdM group). d) The effect of iPSC-MSCs-CdM showed a dose-dependent manner in attenuation 
of ROS generation and apoptosis induced by Dox. The concentration of MDA (d-i) and apoptosis (d-ii) among 
the different groups were also measured among the different groups was measured (*p < 0.01 vs. control group; # 
p < 0.01 vs. Dox group; †p < 0.01 vs. iPSC-MSCs-CdM-10 μ l group; $p < 0.01 vs. iPSC-MSCs-CdM-20 μ l group).
www.nature.com/scientificreports/
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fashion. The cardioprotective effects of CdM derived from iPSC-MSCs are superior to those derived 
from BM-MSCs.
Administration of iPSC-MSCs-CdM attenuates Dox-induced cardiomyopathy in mice. The 
animal experimental protocol is outlined in Fig. 2a. As shown in Fig. 2b, left ventricular ejection frac-
tion (LVEF), fractional shortening (FS) and + dp/dt were significantly decreased in the Dox group at 
week 0 compared with the control group. This confirmed successful establishment of an animal model 
of Dox-induced cardiomyopathy (Fig. 2b; P < 0.01). At 3-weeks, left ventricular systolic pressure (LVSP), 
+ dp/dt and slope of end systolic pressure volume relationship (ESPVR) were significantly decreased in 
the Dox group compared with the control group (Fig.  2c,d-i–iii; P < 0.01). In contrast, LVSP, + dp/dt 
and slope of ESPVR were significantly improved in the BM-MSCs-CdM group and iPSC-MSCs-CdM 
group at 3-weeks compared with the Dox group (Fig.  2c,d-i–iii; P < 0.01). LVSP, + dp/dt and slope of 
ESPVR were also significantly higher in the iPSC-MSCs-CdM group than the BM-MSCs-CdM group 
(Fig. 2d-i–iii; P < 0.01), indicating that iPSC-MSCs-CdM better aids recovery of heart function in AIC. 
Notably, both BM-MSCs-CdM and iPSC-MSCs-CdM groups, but not the Dox group, showed significant 
improvement in + dp/dt at 3-weeks compared with week 0 (Fig. 2e; P < 0.01).
Hematoxylin and eosin (HE) staining revealed a dilated LV chamber, the typical feature of AIC, 
in the Dox group (Fig.  3a-ii) compared with the control group (Fig.  3a-i). Nonetheless injection of 
both BM-MSCs-CdM and iPSC-MSCs-CdM significantly attenuated LV dilatation induced by Dox 
(Fig. 3a-iii,iv).
Cardiac fibrosis was assessed by Sirius red staining (Fig. 3a-v–viii). The ratio of cardiac fibrosis was 
greatly increased in the Dox group compared with the control group (Fig. 3b, 8.1 ± 0.4% vs. 0.3 ± 0.08%; 
P < 0.01). This ratio of cardiac fibrosis was significantly decreased by 22.2% in the BM-MSCs-CdM 
group and by 36.8% in the iPSC-MSCs-CdM group compared with the Dox group (P < 0.01). Notably, 
the ratio of cardiac fibrosis was also significantly lower in the iPSC-MSCs-CdM group than the 
BM-MSC-CdM group (5.1 ± 0.3% vs. 6.4 ± 0.3%; P < 0.01), indicating that iPSC-MSCs-CdM is superior 
to BM-MSCs-CdM in attenuation of Dox-induced cardiac fibrosis (Fig. 3b).
These results demonstrate that injection of BM-MSCs-CdM or iPSC-MSCs-CdM significantly 
improves LV function and decreases myocardial fibrosis in a mouse model of Dox-induced cardiomyo-
pathy. In addition, iPSC-MSCs-CdM is more effective than BM-MSCs-CdM.
Attenuated Dox-induced cardiomyopathy of mice is linked to reduced oxidative stress and 
cardiomyocyte apoptosis in-vivo. The level of ROS in heart tissue among different groups was eval-
uated by MDA. As shown in Fig. 4a, compared with the control group, the concentration of MDA was 
dramatically increased in the Dox group (Fig. 4a, 2.1 ± 0.23 μ mol/g protein vs. 10.8 ± 0.78 μ mol/g pro-
tein; P < 0.01). Nonetheless this concentration was significantly decreased by 24% in the BM-MSCs-CdM 
group and by 40% in the iPSC-MSCs-CdM group compared with the Dox group (P < 0.01). The concen-
tration of MDA was also significantly lower in the iPSC-MSCs-CdM group than in the BM-MSCs-CdM 
group (Fig. 4a, 6.4 ± 0.4 μ mol/g protein vs. 8.2 ± 0.25 μ mol/g protein; P < 0.01).
Next, cell apoptosis in different groups was determined by TUNEL staining. Compared with the con-
trol group, cell apoptosis was significantly increased over the myocardium in the Dox group (Fig. 4b,c, 
25.4 ± 3.2% vs. 1.22 ± 0.3%; P < 0.01). Administration of BM-MSCs-CdM or iPSC-MSCs-CdM signifi-
cantly decreased the cell apoptotic rate (Fig. 4b,c; P < 0.01) over the myocardium compared with the Dox 
group. The cell apoptotic rate was much lower in the iPSC-MSC-CdM group than in the BM-MSCs-CdM 
group (Fig.  4b,c, 9.2 ± 1.5% vs.16.4 ± 1.2%; P < 0.01). These findings indicate that iPSC-MSCs-CdM is 
more potent than BM-MSCs-CdM in reducing ROS and attenuating CMC apoptosis induced by Dox 
in-vivo.
Distinct enrichment of paracrine components between iPSC-MSCs and BM-MSCs. To under-
stand the differential paracrine capacity of BM-MSCs and iPSC-MSCs against Dox-induced cardiotoxic-
ity, we performed a cytokine antibody array that covered 507 human cytokines/chemokines and growth 
factors in the serum free-CdM derived from BM-MSCs and iPSC-MSCs culture. Both BM-MSCs and 
iPSC-MSCs were able to release a wide spectrum of cytokines, chemokines, adipokines, growth factors, 
angiogenic factors and soluble receptors.
Pair-wise comparison of the protein profiling of CdM revealed many common characteristics but also 
some distinct differences. Overall, 214 of 507 factors were commonly detected in both BM-MSCs and 
iPSC-MSCs with <2.0-mean fold difference and P>0.1 from two tailed paired t-test (no significant differ-
ence). Classification of these factors into bioprocesses disclosed that these secreted factors were involved 
in metabolism, immunity, apoptosis, migration and differentiation as well as homeostasis. Nonetheless 
13 factors were preferentially over-represented in BM-MSCs (mean fold difference >2.0 and P < 0.1); 
and 129 of 507 protein factors were preferentially over-represented in iPSC-MSCs (mean fold difference 
>2.0 and P < 0.1).
Our results revealed that most prominent distinctions preferentially found in iPSC-MSCs secretions 
were closely associated with regulation of apoptosis, response to exogenous and endogenous stim-
ulus, cell migration, inflammatory response and cell activation (Table  1). The top 20 protein factors 
over-represented in iPSC-MSCs-CdM were classified into biological processes using the NIH DAVID 
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Figure 2. iPSC-MSCs-CdM transplantation attenuates Dox-induced cardiomyopathy in mice.  
a) Schematic chart showing induction of Dox-induced cardiomyopathy in mice and transplantation of BM-
MSC-CdM or iPSC-MSC-CdM. b) Representative echocardiography photographs showing heart function 
in Control and Dox group at 0 week (i). Compared with control group, left ventricular ejection fraction 
(LVEF), fractional shortening (FS) and + dP/dt were dramatically reduced in the Dox group (ii,iii,iv) 
(*p < 0.01 vs. Control group). c) Representative PV-Loop photographs showing heart function in different 
groups at 3 weeks. d) Effects of BM-MSCs-CdM or iPSC-MSCs-CdM on left ventricular (LV) function 
assessed 3 weeks after CdM injection using cardiac catheterization. Left ventricular systolic pressure (LVSP); 
End systolic pressure volume relationship (ESPVR)(ii); and + dP/dt (iii) (*p < 0.01 vs. Control group; 
#p < 0.01 vs. Dox group; †p < 0.01 vs. BM-MSCs-CdM group). e) J curve showing + dp/dt among different 
groups at 0 weeks and 3 weeks respectively (*p < 0.01 vs. Dox 0 weeks).
www.nature.com/scientificreports/
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Pathway Analysis tool (Fig. 5a). Although we do not know the functional role of each cytokine/growth 
factor or which play the most important role in myocardial repair, many of these factors have been 
individually shown to have positive effects on cardioprotection and to be involved in anti-inflammation 
(GDF-1524, MIF), anti-apoptosis (endothelial monocyte-activating polypeptide-II, Thrombospondin-1), 
anti-oxidation (MIF), and pro-proliferation and migration of cardiac progenitor cells and cardiomyo-
cytes (platelet derived growth factor AA, erythoblastic leukemia viral oncogene homolog 3). Ingenuity 
pathway analysis software identified that the functional networks of the top 20 factors were involved in 
modulation of cell survival (e.g. nuclear factor kappa B signaling), stress response (e.g. mitogen-activated 
protein kinase 1/2 signaling), extracellular matrix metabolism (e.g. matrix metallopeptidase 1, collagens, 
fibronectin), immunomodulation (e.g. transforming growth factor belta signaling, immunoglobulin) 
and inflammation (e.g. interleukinI-1, interleukin-12 signaling) (Fig. 5b-i). Additional analysis revealed 
that the cellular and molecular functions of MIF and GDF-15 factors were significantly associated with 
Figure 3. iPSC-MSCs-CdM transplantation reverses Dox-induced histological change in mice. a) At 3 
weeks after CdM injection, histological examination with Hematoxylin and eosin staining for heart tissue 
among different groups (i–iv). Gross view of heart tissue among Control (i), Dox treated (ii), BM-MSCs-
CdM (iii) and iPSC-MSCs-CdM (iv) treated mice. Compared with control mice (i), enlarged left ventricular 
cavity in doxorubicin treated mice was observed (ii). Sirius red staining showed a different myocardium 
fibrosis among experimental groups (v–viii). b) Quantitative measurement of fibrosis ratio of heart among 
different experimental groups (*p < 0.01 vs. Control group; #p < 0.01 vs. Dox group; †p < 0.01 vs. BM-MSCs-
CdM group).
www.nature.com/scientificreports/
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Figure 4. iPSC-MSCs-CdM transplantation ameliorates ROS generation and apoptosis of 
cardiomyocytes induced by Dox in the heart tissue of mice. a) At 3 weeks after CdM injection, the 
concentration of MDA among different groups was measured (*p < 0.01 vs. Control group; #p < 0.01 vs. 
Dox group; †p < 0.01 vs. BM-MSCs-CdM group, n = 3). b) Representative photographs showing differential 
accumulation of TUNEL positive cells among Control, Dox, BM-MSCs-CdM treatment (BM-MSCs-CdM), 
or iPSC-MSCs-CdM treatment (iPSC-MSCs-CdM) group. c) Quantitative measurement of the apoptotic rate 
of myocardium was expressed as percent of positive TUNEL cells vs. total DAPI positive cells per viewing 
area (*p < 0.01 vs. Control group; #p < 0.01 vs. Dox group; †p < 0.01 vs. BM-MSCs-CdM group, n = 6).
www.nature.com/scientificreports/
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cellular movement, cell cycle, cell metabolism and cell death, cellular development and cellular growth, 
all important for promoting myocardial regeneration (Fig. 5b-ii,iii).
Consistent with the cytokine array results, the concentration of GDF-15 and MIF in iPSC-MSCs-CdM 
and BM-MSCs-CdM was measured by Enzyme-linked Immunosorbent Assay (ELISA) assay. As shown 
in Fig. 5c, the concentration of GDF-15 (Fig. 5c-i, 4113 ± 121 pg/mg protein vs. 559 ± 55 pg/mg protein; 
P < 0.01) and MIF (Fig.  5c-ii, 12316 ± 1244 pg/mg protein vs. 1239 ± 151 pg/mg protein; P < 0.01) was 
significantly higher in iPSC-MSCs-CdM than in BM-MSCs-CdM.
In contrast, the functional enrichment profiles of the secreted factors over-represented in 
BM-MSCs-CdM (Table  2) were more dispersed. Interestingly, the enrichment score for the apoptosis 
group in BM-MSCs-CdM was 5-fold lower compared with iPSC-MSCs-CdM (enrichment score 0.24 
versus 1.25), although the enrichment score for the cell migration group was similar (enrichment score 
0.82 versus 0.65). These observations demonstrate a differential profile of secretions for BM-MSCs 
and iPSC-MSCs that might account for their different therapeutic effect in Dox-induced cardiomyo-
pathy. Bioinformatics analysis has revealed that iPSC-MSCs secretions are preferentially involved in 
anti-apoptosis, anti-inflammation, regulation of cell mobilization and cell proliferation compared with 
BM-MSCs secreted factors.
Enriched GDF-15 and MIF in iPSC-MSCs secretome contributes to attenuation of Dox-induced 
ROS and apoptosis of cardiomyocytes. To explore whether GDF-15 and MIF are responsible 
for the enhanced therapeutic effects of iPSC-MSCs-CdM, we investigated the effects of GDF-15- or 
MIF-depleted iPSC-MSCs-CdM on Dox-induced cardiotoxicity. Both GDF-15 and MIF were depleted 
from iPSC-MSCs-CdM by immunoprecipitation with antibodies specific for GDF-15 and MIF, respectively. 
After depletion, the concentration of GDF-15 was reduced from 4113 ± 121 pg/mg protein to 90 ± 10 pg/mg; 
while MIF was reduced from 12316 ± 1244 pg/mg protein to 120 ± 16 pg/mg; suggesting the immuno-
depletion of GDF-15 and MIF was successful. As shown in Fig.  6a,c, iPSC-MSCs-CdM-inhibited ROS 
generation was remarkably attenuated by depletion of MIF from iPSC-MSCs-CdM (Fig. 6a,c; P < 0.01). 
The reduction in NRCM apoptosis by iPSC-MSCs-CdM was partly attenuated by depletion of GDF-15 
from iPSC-MSCs-CdM (Fig.  6b,e; P < 0.01). In addition, the concentration of MDA was significantly 
increased by depletion of MIF from iPSC-MSCs-CdM compared with iPSC-MSCs-CdM (Fig.  6d; 
P < 0.01). This indicates that MIF and GDF-15 in iPSC-MSCs-CdM contribute to the reduced ROS 
generation and attenuation of NRCM apoptosis.
Immunodepletion of MIF and GDF-15 reduces the efficiency of iPSC-MSCs-CdM to res-
cue Dox-induced cardiomyopathy. To verify the role of MIF and GDF-15 in iPSC-MSCs-CdM 
for the treatment of Dox-induced cardiomyopathy, we compared the cardioprotective effects of 
Secreted factors mRNA Refseq P-value
Mean 
ratio 
(iPSC-
MSCs/
BM-
MSCs) Involved biological process
MIF NM_002415 0.0007 9.0226 Inflammatory response, apoptosis, cell proliferation, oxidation
EMAP-II NM_004757 0.0048 8.4005 Apoptosis, inflammatory response, cell migration, cell proliferation
GDF-15 NM_004864 0.0046 7.4638
inflammation, apoptosis, PI3K/
AKT signaling, Angiogenesis, 
cardioprotective properties, tissue 
differentiation
Osteoprotegerin NM_002546 0.0024 7.2562 Apoptosis, OPG/RANK/RANKL axis
PDGF-AA NM_002607 0.003 5.0133
Response to endogenous stimulus, 
inflammatory response, cell 
migration, cell proliferation
FGF-16 NM_003868 0.0024 4.9466
Actin cytoskeleton, MAPK signaling 
pathway, glycoprotein, response to 
abiotic stimulus,
GFR alpha-4 NM_022139 0.005 4.1354 Lipoprotein, glycoprotein, signal
Thrombospondin-1 NM_003246 0.0029 3.9156
Apoptosis, cell migration, 
inflammatory response, cell 
proliferation
IL-24 NM_006850 0.0021 3.7026 Apoptosis
ErbB3 NM_001005915 0.0016 3.701 Apoptosis, response to endogenous stimulus, cell proliferation
Table 1.  Top 10 secreted factors over-represented in iPSC-MSCs.
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Figure 5. Profile of paracrine factors in the conditioned medium from iPSC-MSCs. a) Functional 
classification of the top 20 factors preferentially over-presented in iPSC-MSC-CdM. Here the p-value, or 
called EASE score, is a modified one-tail Fisher exact probability value used for gene-enrichment analysis 
in DAVID system. Each gene group has been assigned several annotation terms, and each gene group’ 
enrichment score stands for the geometric mean of negative denary logarithm of EASE scores of those terms 
involved in this group. Groups with enrichment score higher than 0.6 were shown in the figure (Enrichment 
score for group A: 1.25; B: 1.14; C: 0.81; D: 0.65; E: 0.61). b) Interactions and functional network identified 
by IPA. Genes in red indicate over-expressed genes found in iPSC-MSCs secretion compared with BM-MSC 
secretion. Deeper color means higher fold ratio for iPSC-MSCs- compared with BM-MSCs-secretion (i). 
MIF involved molecular and cellular functions identified by IPA. Ranged p-values are shown in negative 
denary logarithm form in y-axis (ii). GDF-15 involved molecular and cellular functions identified by IPA. 
Ranged p-values are shown in negative denary logarithm form in y-axis (iii). c) The concentration of GDF-
15 among different groups was measured (i) (*p < 0.01 vs. BM-MSCs-CdM group, n = 3). The concentration 
among different groups was measured (iii) (*p < 0.01 vs. BM-MSCs-CdM group, n = 3).
www.nature.com/scientificreports/
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iPSC-MSCs-CdM with immunodepletion of MIF and GDF-15 in iPSC-MSCs-CdM in a mouse 
model of AIC. Three weeks following CdM injection, the LVSP, LV + dp/dt and ESPVR were remark-
ably reduced in the iPSC-MSCs-CdM-MIF/GDF-15(− ) group compared with the iPSC-MSCs-CdM 
group (Fig.  7a-i–iii; P < 0.01). Sirius Red staining also demonstrated that fibrosis was much higher in 
the iPSC-MSCs-CdM-MIF/GDF-15(− ) group compared with the iPSC-MSCs-CdM (Fig.  7b-i–iv,vi; 
P < 0.01).We also examined the effects of recombinant MIF and GDF-15 with the same concentration 
of MIF/GDF-15 in iPSC-MSC-CdM on heart function in a mouse model of AIC. Three weeks follow-
ing MIF/GDF-15 injection, LVSP, LV + dp/dt and ESPVR were significantly higher in the MIF/GDF-15 
treated group than in the Dox group (Fig. 7a-i–iii; P < 0.01). Sirius Red staining showed that the fibrosis 
ratio was markedly reduced in the MIF/GDF-15 treated group compared with the Dox group (Fig. 7b-i–
vi; P < 0.01). There was also a significant difference between iPSC-MSCs-CdM and MIF/GDF-15 in heart 
function or fibrosis ratio (Fig. 7a,b; P < 0.01). These results indicate that enrichment of iPSC-MSCs-CdM 
with MIF and GDF-15 contributed to cardioprotection against Dox-induced cardiomyopathy.
Discussion
The findings of this study demonstrate that both human iPSC-MSCs-CdM and BM-MSCs-CdM provide 
cardioprotection against Dox-induced cardiomyopathy by reducing ROS and cardiomyocyte apoptosis. 
The therapeutic effects of iPSC-MSCs-CdM are more potent than those of BM-MSCs-CdM. In particu-
lar, iPSC-MSCs-CdM enriched with MIF and GDF-15 contributes to the reduced ROS generation and 
apoptosis of cardiomyocytes induced by Dox.
Although iPSC-MSCs and BM-MSCs share many common properties, iPSC-MSCs have several 
unique advantages such as their higher proliferative capacity and a more robust differentiation poten-
tial22. The potential risk of tumor formation and poor cell engraftment with iPSC based transplanta-
tion nonetheless remains a concern. As the majority of the proposed benefits of MSC-based therapy is 
attributed to their paracrine effects, rather than direct trans-differentiation21,25,26, this prompted us to 
compare the potential therapeutic effects of CdM derived from human BM-MSCs and iPSC-MSCs in 
the treatment of Dox-induced cardiomyopathy.
In this study, we confirmed that cardiomyocyte apoptosis induced by increased ROS generation is 
one of the major mechanisms of Dox-induced cardiomyopathy27–29. Consistent with our prior stud-
ies23,30, we demonstrated that compared with BM-MSCs-CdM, iPSC-MSCs-CdM provides stronger 
anti-oxidative stress and anti-apoptotic actions that contribute to superior therapeutic efficacy in atten-
uation of Dox-induced cardiomyopathy. Our findings from antibody array showed that iPSC-MSCs and 
BM-MSCs not only release similar cytokines but also many distinct paracrine factors that may account 
for the superior therapeutic effects of iPSC-MSCs-CdM. Analysis of the highly expressed cytokines of 
Secreted factors mRNA Refseq P-value
Mean 
ratio 
(BM-
MSCs/
iPSC-
MSCs) Involved biological process
MMP-15 NM_002428 0.024 42.55319
Phosphoprotein, 
transmembrane, glycoprotein, 
calcium ion binding, 
polymorphism, disulfide bond
Activin RII A/B NM_001106 0.002 5.885815 Cell differentiation
EGF R (ErbB1) NM_005228 0.0603 5.630631 Cell migration, cell proliferation, cell cycle, apoptosis
Activin A NM_002192 0.0403 5.51572
mesoderm induction, cellular 
proliferation and differentiation, 
cell survival
AR (Amphiregulin) NM_001657 0.03 4.512635 Cell proliferation, mitogen
CD30 Ligand NM_001244 0.0328 3.318951 Cell proliferation, apoptosis
S100 A8/A9 NM_002965 0.0844 3.063725 Inflammatory response, cell migration
CCR7 NM_001838 0.0167 2.783964 Inflammatory response, cell migration of memory T cells
Glypican 3 NM_001164617 0.0585 2.45821 Cell division, cell differentiation
PDGF R alpha NM_006206 0.0827 2.278943 Cell migration, cell proliferation
VEGF R2 (KDR) NM_002253 0.069 2.198769 Cell migration, cell proliferation
SIGIRR NM_021805 0.0641 2.042901 Inflammatory response
Chem R23 NM_001142345 0.0029 2.024701 Cell migration
Table 2.  Top 13 secreted factors over-represented in BM-MSCs.
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Figure 6. Role of MIF and GDF-15 in iPSC-MSC-CdM-attenuated Dox-induced cardiotoxity.  
a) Representative photographs showing ROS generation among Control, doxorubicin (Dox), iPSC-MSCs-
CdM-control antibody treatment (iPSC-MSCs-CdM-ConAb), or MIF and/or GDF-15 depleted iPSC-
MSCs-CdM treatment. b) Representative photographs showing the apoptosis of NRCMs among Control, 
doxorubicin (Dox), iPSC-MSCs-CdM -control antibody treatment (iPSC-MSCs-CdM-ConAb), or MIF 
and/or GDF-15 depleted iPSC-MSCs-CdM treatment. c) Quantitative measurement of immunofluorescent 
intensity of ROS among different experimental groups after normalized to control group (*p < 0.01, n = 3). 
d) The concentration of MDA among different groups was measured (*p < 0.01, n = 3). e) Quantitative 
measurement of apoptotic rate of NRCMs among different experimental groups. Quantitative measurement 
of ROS and apoptotic rate was counted from five viewing fields in each group and triple experiments were 
performed (*p < 0.01).
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iPSC-MSCs-CdM showed that those secreted factors are involved in anti-apoptosis, anti-inflammation/
oxidation, and regulation of cell mobilization and reactivation. Among them, we detected a > 9.0-fold 
higher level of MIF that was over-represented in iPSC-MSCs-CdM compared with BM-MSCs-CdM. MIF 
confers potent cardioprotective effects by reducing oxidative stress31,32 and activates the cardioprotective 
AMP-activated protein kinase pathway. Similarly, a > 7.5-fold higher level of GDF-15 was strikingly 
Figure 7. Immunodepletion of MIF and GDF-15 in iPSC-MSCs-CdM fails to rescue the Dox-induced 
cardiomyopathy. a) Different cardioprotective effects of iPSC-MSCs-CdM or iPSC-MSCs-CdM-MIF/GDF-
15(− ) or MIF/GDF-15 transplantation on LV geometry and function, including LVSP (i), + dp/dt (ii) and 
ESPVR (iii) assessed 3 weeks after CdM injection using cardiac catheterization (*p < 0.01 vs. Control group; 
#p < 0.01 vs. Dox group; †p < 0.01 vs. iPSC-MSCs-CdM group; $p < 0.01 vs. iPSC-MSCs-CdM group n = 6). 
b) Sirius red staining showing a different myocardium fibrosis among Control group (i); Dox group (ii); 
iPSC-MSCs-CdM (iii) group; iPSC-MSCs-CdM-MIF/GDF(− ) group (iv); MIF/GDF-15 (v). Quantitative 
measurement of fibrosis of heart among different experimental groups (v) (*p < 0.01 vs. Control group; 
#p < 0.01 vs. Dox group; †p < 0.01 vs. iPSC-MSCs-CdM group, n = 6; $p < 0.01 vs. iPSC-MSCs-CdM group 
n = 6).
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over-presented in iPSC-MSCs-CdM compared with BM-MSCs-CdM. GDF-15 has been recently identi-
fied as a critical cardioprotective factor with anti-apoptotic, anti-inflammatory and anti-cardiac remode-
ling properties in response to myocardial injury33. The therapeutic effects of iPSC-MSC-CdM are greatly 
abolished by neutralizing MIF and GDF-15. Insulin-like growth factor (IGF)-1, a well-known key factor 
that activates resident endogenous cardiac stem/progenitor cells34; and Neuropilin-2, a key factor that 
promotes cardiac progenitor cells (CPC) and endothelial cell survival and migration35, were also greater 
than two fold higher in iPSC-MSCs-CdM than in BM-MSCs-CdM.
As shown in the present study, a cytokine cocktail derived from MSC-derived CdM may provide a 
unique therapeutic tool for the treatment of AIC. Despite major advances in the prevention and treat-
ment, such as the use of angiotensin converting enzyme inhibitors alone or with beta-blockers, AIC 
remains a major cause of morbidity and mortality in cancer survivors36. The use of iPSC-MSCs-CdM 
may be a novel therapeutic approach to prevent or treat AIC, especially in those in whom conventional 
medical therapy has failed. There is an emerging interest to apply MSC-derived secretome or exosome 
for organ repair and/or regeneration21,37. Recently, transplantation of stem cell-conditioned medium, 
instead of stem cells, has been shown to be effective for tissue/cell repair in a range of conditions such 
as ischemic heart disease38–40, retinal ischemia41, acute lung injury42, chemical-induced colitis, enteric 
neuropathy43 and spinal cord injury44. Delivery may be by a single (immediate or delayed) administra-
tion38,40,41,43 or continuous administration over a short period of time39,44. MSCs can release many ben-
eficial cytokines that are important in cardiac protection, but they can also release potentially harmful 
factors45. Thus optimization of MSC paracrine factors is preferable in order to maximize their beneficial 
effects. In this study, we identified two crucial cytokines, GDF-15 and MIF, which are highly presented 
in the iPSC-MSCs-CdM for heart repair, that offer great potential for the future development of a ther-
apeutic MSC-secreted cocktail. A similar approach may also be applied to optimize the paracrine profile 
of iPSC-MSCs-CdM for myocardial repair in different cardiovascular diseases.
There are many advantages of stem cell conditioned medium for tissue repair. Nonetheless in certain 
disease conditions, transplantation of stem cells may be superior as it enables stem cell differentiation 
and engraftment to replace damaged myocardial tissue46.
There are some limitations to this study. First, only the two most prominent cytokines in 
iPSC-MSCs-CdM secretion were analyzed. The functions of other factors that are significantly enriched 
in iPSC-MSCs-CdM need further investigation. Second, there is increasing evidence that paracrine factor 
profiling of MSCs is highly dependent on the microenvironment30,47. MSCs are sensitive to the inflamma-
tory microenvironment and may polarize into two distinct phenotypes following specific toll like receptor 
stimulation, and result in different immune-modulatory effects and distinct secretions48. Polarization of 
at-rest MSCs into a pro-inflammatory phenotype (MSC1) or an immunosuppressive phenotype (MSC2) 
that responds to different stimulation provides an attractive model to understand the multiple facets of 
MSCs49. We harvested at-rest MSC secretion in vitro that may not truly reflect MSC-mediated myocar-
dial repair in vivo. Third, the optimal dose of CdM for cardioprotection has not been determined. Fourth, 
the long-term impact of CdM on heart function and survival was not investigated in this study.
This study provides evidence that iPSC-MSCs-CdM is more effective than adult BM-MSCs-CdM for 
cardioprotection against Dox-induced cardiomyopathy. The distinct protective effect of iPSC-MSCs-CdM 
is associated with some enriched important cytokines such as MIF and GDF-15 that are involved in 
anti-apoptosis, anti-inflammation/oxidation, regulation of cell mobilization and reactivation. We have 
provided evidence that iPSC-MSCs-CdM may serve as a novel therapeutic approach for the future devel-
opment of “cell-free” therapy for cardiovascular repair.
Methods
Cell culture. Characterized BM-MSCs from healthy adults were commercially acquired from Cambrex 
BioScience (Cat. No. PT-2501). Human iPSC-MSCs derived from iPSC lines have been previously 
described22. At least two iPSC-MSC lines (IMR90-iPSC-MSCs and Lee NL-iPSC-MSCs; passage 9 ~ 10) 
and two BM-MSC lines (passage 4 ~ 5) were used in this study. MSCs were cultured with Dulbecco’s 
Modified Eagle’s medium (DMEM) plus 10% fetal calf serum (GIBCO), basic fibroblast growth factor 
(bFGF, 5 ng/mL), and epidermal growth factor (EGF, 10 ng/mL). Cells were diluted at a ratio of 1:3 when 
they reached 70–80% confluence.
Preparation of CdM and cytokine assays. As described previously23, CdM of cultured MSCs was 
prepared. In brief, MSCs were trypsinized and plated on a 15-cm plate, a total of 5 × 106 cells. Twenty-four 
hours later, the regular culture medium was replaced with 15 ml of serum- and antibiotic-free DMEM 
(no EGF and bFGF). After a further 24 hours, the supernatant was aspirated gently, filtered through a 
0.22 μ m filter, then transferred to ultrafiltration conical tubes (Amicon Ultra-15 with membranes selec-
tive for − 5 kDa), and finally centrifuged (4,000 g for 30 min at 4 °C) to concentrate the CdM. The final 
concentration was adjusted to 20 times that of the collected CdM.
Cytokine assay of MSC-CdM was performed using RayBio® Cytokine antibody array as previously 
described21. Briefly, a total of 200 μ l of BM-MSCs-CdM or iPSC-MSCs-CdM was assayed for the pres-
ence of cytokines and other proteins according to the manufacturer’s instructions (RayBiotech, Norcross, 
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GA. Cat No: AAH-BLG-1-4). Quantitative human cytokines were measured using customized Bio-Plex 
cytokine assay (Bio-Rad Laboratories, Hercules, CA; Cat No. M50007VNJK and MF00038C9E) accord-
ing to the manufacturer’s instructions.
Comparison of protein expression in iPSC-MSCs-CdM and BM-MSCs-CdM. The proteins in 
two iPSC-MSCs-CdMs and two BM-MSCs-CdMs were compared. According to the expression value, 
the proteins were be classified into three types: commonly detected in both BM-MSCs and iPSC-MSCs 
with < 2.0-mean fold difference and P> 0.1 from two tailed paired t-test, preferentially expressed in 
BM-MSCs (mean fold difference>2.0 and P < 0.1), or preferentially expressed in iPSC-MSCs (mean fold 
difference >2.0 and P < 0.1). In each group, gene-enrichment analysis and functional classifications were 
conducted by The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. Each 
protein group is associated with several annotation terms, and each term is coupled with a p-value, or 
so-called EASE score, which is a modified one-tail Fisher exact probability value. The protein groups’ 
enrichment score stands for the geometric mean of negative denary logarithm of EASE scores of those 
terms involved in this group. Interactions and the functional network centered on certain factors were 
identified by INGENUITY pathway analysis (IPA).
NRCMs and culture. The NRCMs were isolated and cultured as described previously50. Briefly, hearts 
were quickly removed from neonatal Wistar rats (0- to 1-day-old) sacrificed by decapitation, rinsed four 
times with modified Hank’s solution, and cut into small pieces on ice. The tissue fragments were warmed 
in a 50 ml tube in a water bath with a magnetic bar for 10 min at 37 °C. After discarding the supernatant, 
the minced myocardium was digested with fresh pre-warmed 0.2% trypsin for 5 min at 37 °C, and then 
the supernatant was collected gently and transferred to a 50 ml tube on ice containing 7 ml fetal bovine 
serum. These two steps were repeated to collect all the supernatant that was then centrifuged at 156.8 g 
for 5 min to collect the cells. Cells were re-suspended in NRCM culture medium to reduce fibroblast 
contamination. Finally, the supernatant was aspirated gently, and the cells plated in 24-well plates con-
taining collagen-coated glass coverslips at a density of 2 × 105 cells/ml. Culture media was changed every 
day. NRCMs were assigned to four different culture conditions for 24 hours: 1) control group; 2) 1 μ M 
Dox and 50 μ l serum- and antibiotic-free DMEM; 3) 1 μ M Dox and 50 μ l BM-MSCs-CdM; and 4) 1 μ M 
Dox and 50 μ l iPSC-MSCs-CdM. We employed the same amount of total protein from iPSC-MSC-CdM 
and BM-MSC-CdM in the studies. A higher concentration of iPCS-MSC-CdM was adjusted with basal 
medium (Phenol free DMEM) for the same volume (50 μ l) as BM-MSC-CdM (50 μ l) before use. To 
assess the dose-dependent effect of iPSC-MSCs-CdM, NRCMs were assigned to four different culture 
conditions for 24 hours: control group; 1) 1 μ M Dox and serum- and antibiotic-free DMEM; 2) 1 μ M 
Dox and 10 μ l iPSC-MSCs-CdM; 3) 1 μ M Dox and 20 μ l iPSC-MSCs-CdM; 4) 1 μ M Dox and 50 μ l 
iPSC-MSCs-CdM.
Detection of ROS and apoptosis. To detect the generation of ROS induced by Dox, H2DCFDA 
staining was performed. Briefly, NRCMs were cultured in 24-well plates with collagen-coated glass cover-
slips, and treated as described above. Then NRCMs were incubated with H2DCFDA (10 μ M; Invitrogen) 
for 10 min at 37 °C in the dark. Subsequently, cells were washed with PBS twice and mounted with 4′ , 
6-diamidino-2-phenylindole (DAPI). Fluorescence intensity for ROS signal (percent arbitrary fluores-
cence units, % AFU) was measured on 300 cells using Image J software. Finally, fluorescence intensity 
was calculated from five different view fields of each group in three independent experiments.
To demonstrate the protective effects of MSCs-CdM on Dox-induced apoptosis of NRCMs, TUNEL 
staining was performed. Cell samples were fixed with fixation solution, and incubated with blocking 
solution and then with permeabilisation solution. The heart sections were washed and incubated with 
1 μ g/ml Proteinase K/10 mM Tris solution for 15 min at room temperature and washed twice in PBS. 
Finally, all samples were incubated with 50 μ l TUNEL reaction mixture in a humid chamber for 1 hour 
at room temperature. Sections were then washed 3 times in PBS, mounted with DAPI, observed under 
a fluorescent microscope and finally photographed.
ELISA. According to the manufacturer’s instructions, the concentration of GDF-15 and MIF in the 
CdM from iPSC-MSCs and BM-MSCs was measured using a human GDF-15 Elisa kit (Human GDF-15 
DuoSet, DY957, R&D systems) and human MIF Elisa kit (Human MIF DuoSet, DY289, R&D systems) 
respectively.
Immunodepletion of GDF-15 and MIF from iPSC-MSCs-CdM. GDF-15 and MIF were depleted 
from iPSC-MSCs-CdM as described previously51. Briefly, 0.5 μ g of anti-GDF-15 (Clone 147627; R&D) 
and/or anti-MIF antibodies (Clone12302; R&D) or normal human IgG control antibody (1-001-A; R&D) 
were mixed with a suspension (50% slurry) of protein G-agarose beads in PBS at 4 °C for 1 hour with 
intermittent shaking. Following recovery by centrifugation, beads were washed three times and used for 
immunodepletion of GDF-15 and MIF. iPSC-MSC-CdM (1 ml) was incubated with protein G-agarose 
beads immobilized with anti-GDF-15 and/or anti-MIF antibodies or control human antibody for 1 hour 
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at 4 °C. Immune complexes absorbed on protein G-agarose beads were precipitated by centrifugation. 
Finally, iPSC-MSCs-CdM was collected and centrifuged to 50 μ l and then used immediately.
Animal model. All animal experiments were performed in accordance with relevant guidelines and 
regulations by the University of Hong Kong and approved by the Committee on the Use of Live Animals 
in Teaching and Research (CULTAR) (Approval ID:3358-14). The animal model of AIC was induced 
in adult mice (6–8 weeks, ICR strain) by intraperitoneal injection of Dox (3 mg/kg, 3 times per week 
with a total cumulative dose of Dox 18 mg/kg)52. In the negative control group, mice were injected with 
an equal volume of saline. To confirm the successful creation of an animal model of AIC, echocardi-
ography and invasive hemodynamic assessment were performed to measure heart function (n = 6) one 
week following completion of Dox injection. Since a single direct intramyocardial injection of 100 μ l of 
MSC-CdM into rat heart53, or 50 μ l of adipose-derived stem cell (ADSC)-CdM into mice heart had been 
reported to improve ischemic heart function54, we decided to inject 50 μ l of MSCs-CdM into mice heart 
in this study. A further group of mice with AIC were randomized to receive intramyocardial injection 
of 1) phosphate-buffered saline (Dox group, n = 16); 2) 50 μ l BM-MSCs-CdM (BM-MSCs-CdM group, 
n = 13); or 3) 50 μ l iPSC-MSCs-CdM (iPSC-MSCs-CdM group, n = 12) at 4 sites of the left ventricle 
(LV). Three weeks after CdM injection, invasive hemodynamic measurements were performed. All mice 
were then sacrificed and detailed histological examination was performed to assess myocardial fibrosis, 
apoptosis and oxidative stress.
In order to verify the role of GDF-15 and MIF in iPSC-MSCs-CdM for the treatment of AIC, additional 
groups of mice with AIC were randomized to receive intramyocardial injection of 1) phosphate-buffered 
saline (Dox group, n = 12); 2) 50 μ l iPSC-MSCs-CdM (iPSC-MSCs-CdM group, n = 12) or 3) 50 μ l 
iPSC-MSCs-CdM with depletion of MIF and GDF-15 (iPSC-MSCs-CdM-MIF/GDF-15(− ) group, 
n = 12) 4) 50 μ l MIF/GDF-15 (MIF/GDF-15 group, n = 12) at 4 sites of the left ventricle (LV). The 
concentrations of MIF and GDF-15 mixture were the same as those in iPSC-MSCs-CdM. Briefly, in 
iPSC-MSCs-CdM, we first measured the concentration of GDF-15 was 4113 ± 121 pg/mg and MIF was 
12316 ± 1244 pg/mg. Total protein concentration of iPSC-MSCs-CdM was 1.09 mg/ml. Then the concen-
tration and total amount of GDF-15 and MIF in 50 μ l of iPSC-MSCs-CdM were able to be calculated. 
Next we made concentrations of GDF-15 at 4.48 ng/ml and MIF at 13.42 ng/ml in ddH20 solution to 
meet the same concentrations of GDF-15 and MIF presented in iPSC-MSCs-CdM. The total amounts 
of GDF-15 (0.224 ng) and MIF (0.67 ng) in 50 μ l were used for injection. Human MIF (Catalog.300-69) 
and GDF-15 (Catalog.120-28) recombinant cytokines were purchased from PeproTech. Three weeks later, 
hemodynamic measurements were performed, and then all mice were sacrificed for histological study.
Cardiac function assessment. At 3 weeks after CdM injection, mice were anesthetized (intra-peri 
toneal injection of 100 mg/kg of ketamine and 20 mg/kg of xylazine) to undergo transthoracic echocar-
diography and invasive hemodynamic assessment. M-mode echocardiogram was performed to measure 
LVEF and FS as previously described55. A 1.4-Fr high-fidelity microtip catheter connected to a pressure 
transducer (Millar Instruments, Houston, TX, USA) was inserted into the LV cavity via the internal jugu-
lar artery to evaluate LV pressure and dP/dt using the PowerLab system (AD Instruments, Inc., Colorado 
Springs, CO, USA)55. In this study, the echocardiographic and hemodynamic analyses were performed 
by an experienced investigator who was blinded to the experimental information.
Histological analysis. All mice were sacrificed following hemodynamic study; hearts were harvested 
and fixed with 10% buffered formalin and embedded in paraffin, then sectioned to 5 μ m slides. HE stain-
ing and Sirius red staining were performed. The ratio of fibrotic area was quantified with 6 randomly 
chosen high power fields for each heart section, 6 mice for one group and analyzed using Image J with 
additional threshold color plug-in to process the file images.
MDA assay. The concentration of MDA in the heart tissues and treated NRCMs from different exper-
imental groups was measured using the Thiobarbituric Acid Reactive Substance Assay Kit (Cayman 
Chemical), according to the manufacturer’s instructions.
Statistical analysis. Values are expressed as mean ± standard deviation. The significant differences 
between groups were analyzed with unpaired Student t test for two groups or one-way ANOVA, followed 
by Bonferroni test for more than 2 groups. A value of P < 0.05 was considered statistically significant.
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